However, significant restraints persist, particularly the premium pricing of these therapies and limited insurance coverage in emerging markets, which restricts patient access
Additionally, SRY-box transcription factor 9 (Sox9) and Krppel-like factor 4 (Klf4) transcription factors, are Paneth and goblet cell-specific differentiation factors [22, 23]
In the drugs best showing so far, the ATTAIN-1 trial, people taking orforglipron lost on average 12.4% of their baseline weight, a notch below the roughly 14% weight loss seen in similar trials of Novo Nordisks injectable Wegovy and also below the typical results seen with Eli Lillys tirzepatide, a dual GLP-1/GIP medication
They often don't consider inflammation until it contributes to a larger health problem
Unfortunately, this will mean that lower wage employees unable to afford the upfront cost will be less likely to obtain the benefits from GLP-1 medications
Microdosing refers to the practice of consuming a low dose of GLP-1 drugs (off-label) instead of the standard therapeutic dose to achieve mild weight loss or appetite benefits with fewer side effects at a lower cost